Today in Peptides
FDA Pharmacy Compounding Advisory Committee (PCAC) meeting: July 23-24, 2026
The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24, 2026 to review bulk drug substances nominated for pharmacy compounding, including peptides such as BPC-157 and TB-500.
Why it matters: The committee's recommendations could affect whether these and other peptides remain available as pharmacy-compounded preparations. This is an informational heads-up, not medical or legal advice.
Michigan HB 6172: Animals: animal shelters; cross-references to 1969 PA 287 in public health code; update. TIE BAR WITH: HB 6167'26
bill electronically reproduced 07/03/2026
Latest Updates
The Food and Drug Administration (FDA, Agency, or we) is extending the effective date of the notice published in the Federal Register on May 27, 2026, titled Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-C...
Read brief →The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice entitled "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act" th...
Read brief →The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry titled "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products." FDA has revis...
Read brief →The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry (GFI) #114 entitled "Effectiveness of Anthelmintics: Specific Recommendations for Chickens--Gallus gallus." This guidance has b...
Read brief →The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 202608 for Methylphenidate Hydrochloride (HCl) Extended-Release (ER) tablets, 27 milligrams (mg), 36 mg, and 54 mg, held by ...
Read brief →The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 20, 2026. The document announced the withdrawal of approval of 11 abbreviated new drug applications (ANDAs) from multiple applic...
Read brief →Referred to committee
Read brief →The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft guidance for industry entitled "Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products." Whe...
Read brief →The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspecti...
Read brief →Received in the Senate; read by title. Rules suspended. Read second time by title and concurred in by a vote of 33 yeas and 0 nays. Ordered returned to the House.
Read brief →The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required...
Read brief →The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourci...
Read brief →The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations ...
Read brief →Committee recommended ought to pass with an amendment, striking out all after the enacting clause and inserting the text of H5510, and referred to the committee on House Steering, Policy and Scheduling
Read brief →Read by title, under the rules, referred to the Committee on Health and Welfare.
Read brief →The National Eye Institute, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the paten...
Read brief →03/30/2026 Committee recommended measure be held for further study
Read brief →Secretary of State Chapter 115 05/27/26
Read brief →The National Cancer Institute (NCI), an institute/center of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the license opportunity for the invention listed below, which is owned b...
Read brief →Died in House Committee
Read brief →Stricken from Calendar by Rule 1507
Read brief →Died on House Calendar
Read brief →REFERRED TO COMMITTEE ON HEALTH POLICY
Read brief →The National Center for Advancing Translational Sciences (NCATS), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the licensing opportunities for the inventions lis...
Read brief →This final rule revises the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; makes changes relating to Medicare graduate medical education (GME) for teaching hos...
Read brief →Filed
Read brief →Filed
Read brief →First consideration
Read brief →Resolution to discharge committee from further consideration of this bill presented
Read brief →The Food and Drug Administration (FDA or we) is amending the color additive regulations to provide for the expanded safe use of butterfly pea flower extract as a color additive in ready-to-eat cereals, crackers, snack mixes, hard pretzels, ...
Read brief →(H) DUE BACK FROM GOVERNOR 6/18/26
Read brief →referred to Committee on Health Policy
Read brief →Pursuant to Joint Rule 310.3 Placed in Legislative Files (DEAD)
Read brief →Act No. 34 of 2025
Read brief →Died on House Calendar
Read brief →The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the request for information and comments notice entitled "Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Pro...
Read brief →The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the publication of the NIOSH List of Hazardous Drugs ...
Read brief →The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Dietary Intake of Polyunsaturated Fatty Acids and Plasma ...
Read brief →The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on Dietary Saturated Fat Replacement and Plasma Lipid and Ca...
Read brief →Daily Peptide News. No Spam.
Research, regulatory, and vendor updates. See FTC disclosure.